2025
The Influence of Age on Patient-Reported Outcomes (PROs) Endpoints on the S1826 Cross-Network Phase III trial of Advanced-Stage, Classic Hodgkin Lymphoma (cHL) (3891/4500)
K Davison;J Unger;H Li;S Castellino;H Dillon;T Hernandez;S Rutherford;A Punnett;M LeBlanc;J Song;S Smith;A Evens;K Kelly;J Friedberg;A Herrera;S Parsons ASH Annual Meeting (December 6-9, 2025, Orlando, FL)
3-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;B Hu;C Moskowitz;C Forlenza;A Doan;A Lamble;D Hodgson;M Knopp;P Hernandez;R Little;M Shipp;RM Crump;B Kahl;JP Leonard;S Smith;J Song;K Kelly;J Friedberg ASH Annual Meeting (December 6-9, 2025, Orlando, FL)
CtDNA Analyses of Molecular Tumor Burden Improve Response Assessment in Patients with Advanced Stage Classic Hodgkin Lymphoma Treated on SWOG S1826
J Paczkowska;M Kaszkowiak;M LeBlanc;C Stewart;A Herrera;J Fernandez del Castillo;S Castellino;S Rutherford;A Evens;K Davison;H Li;D Neuberg;M Murakami;J Makker;B Kahl;J Leonard;N Bartlett;S Smith;J Song;K Kelly;G Getz;JW Friedberg;M Shipp ASH Annual Meeting (December 6-9, 2025, Orlando, FL)
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
P Torka;A Bock;E Nazarenko;Y Xu;J Vaughn;S Thiruvengadam;A Major;K Sekaran;D Reef;C Lee;G Smilnak;E Luttwak;V Patel;H Shah;A Ip;G Baek;R Mynam;D Sano;D Gerber;A Falade;M Palmeri;R Mrad;M Iqbal;J Sharp;T Voorbees;P Geethakumari;J Rbodes;U Durani;H Cherng;Y Karimi;P Pophali;M Di;T Feldman;J Svoboda;K Shanmugasundaram;A Niu;N Grover;R Karmali;A Herrera;C Diefenbach;N Epperla ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3622 poster
Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study
Nancy Bartlett, MD ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #1851
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. Reply
Herrera AF N Engl J Med. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269
PMid: PMID39752312
2024
Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg New England Journal of Medicine Oct 17;391(15):1379-1389
PMid: PMID39413375 | PMC number: PMC11488644
Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;S Parsons;F Keller;R Drachtman;A Lambert;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;R Little;M Smith;H Dillon;J Song;S Smith;J Friedberg;K Kelly ISHL (October 26-28, Cologne, Germany), oral
Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens ISHL (October 26-28, Cologne, Germany), oral
2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg ISHL (October 26-28, 2024 Cologne, Germany), oral
2021
An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826
S Castellino;M Leblanc;A Herrera;S Parsons;A Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly INTERNATIONAL SYMPOSIUM ON CHILDHOOD, ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA (ISCAYAHL) (5/13-16/20, Berlin, Germany)
Addressing the Paucity of AYA Clinical Trials Through Pediatric and Adult Partnership
S Parsons;M Roth AYA Global Congress (December 2, 2021), plenary presentation, oral, no publication
